CARD ID | 593 | |
Type of strain | Targeted mutant. | |
Strain name | B6;129-Serpinc1tm1 | |
Internal Code | AT(+/-), B6;129-Serpinc1tm1 | |
Submitter | Unknown Unknown | |
Submitter affiliation or code | ||
Stock Type | ||
Material Transfer Conditions |
In the following cases, you do not need to be in contact.
|
|
Production method | in-house breeding | |
Origin (In-house) | Organization | Nagoya University School of Health Sciences |
Organization code | ||
Developer | KOJIMA TETSUHITO(HIDEHIKO SAITO) | |
Origin (From other organizations) | Organization | |
Organization code | ||
Developer | ||
Year introduced | ||
Introduced Generation | ||
Remarks |
Gene symbol | Serpinc1 |
Gene name | serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1 |
Allele symbol | Serpinc1tm1 |
Allele name | serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1, targeted mutation 1 |
MGI | MGI:88095, |
Chromosome | 1 (69.75) , |
Gene classification | Targeted or trapped gene(knockout etc.) |
Method | Electroporation |
OMIM | OMIM ID: 107300 Human Gene Symbol: SERPINC1, |
Author | Kazuhiro Ishiguro,Tetsuhito Kojima, Kenji Kadomatsu, Yukiko Nakayama, Akira Takagi, Misao Suzuki, Naoki Takeda, Masafumi Ito, Koji Yamamoto, Tadashi Matsushita, Kazuo Kusugami, Takashi Muramatsu, and Hidehiko Saito |
Title | Complete antithrombin deficiency in mice results in embryonic lethality |
Journal | J. Clin. Invest. |
Volume | 106 |
Page | 873-878 |
Year | 2000 |
PMID | 11018075 |
Disease name, Applicable field | Development |